Risk of myopathy and hepatotoxicity in patients with cancer receiving statin therapy: Systematic review of randomized controlled trials.

This document is a systematic review of randomized controlled trials (RCTs) that assess the risk of myopathy and hepatotoxicity in patients with cancer receiving statin therapy. Statins are commonly used to lower cholesterol and reduce the risk of cardiovascular events. The review found that the risk of severe transaminitis or clinically relevant myopathy events in patients with cancer receiving statin therapy is very low. However, the study acknowledges limitations such as a small number of patients and short follow-up periods. Overall, the data suggest that statin therapy is generally safe for patients with cancer, but individual patient factors should also be considered. [Extracted from the article]